{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:42:29Z","timestamp":1774327349801,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HS018517"],"award-info":[{"award-number":["R01HS018517"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.intimp.2020.107260","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T20:04:45Z","timestamp":1608667485000},"page":"107260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"91","author":[{"given":"Alison D.","family":"Petro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryant R.","family":"England","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harlan","family":"Sayles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Duryee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos D.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios A.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey M.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2020.107260_b0005","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2020.107260_b0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.38969","article-title":"Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis","volume":"67","author":"Thiele","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2020.107260_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.intimp.2018.01.022","article-title":"Malondialdehyde-acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions","volume":"56","author":"Mikuls","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2020.107260_b0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/rheumatology\/kex212","article-title":"Enrichment of malondialdehyde-acetaldehyde antibody in the rheumatoid arthritis joint","volume":"56","author":"Mikuls","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.intimp.2020.107260_b0025","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/ard.2009.122739","article-title":"Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis","volume":"69","author":"Miriovsky","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2020.107260_b0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2020.107260_b0035","article-title":"Antibody to Malondialdehyde-Acetaldehyde (MAA) adducts serve as biomarkers of treatment response in rheumatoid arthritis","volume":"67","author":"Mikuls","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107260_b0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2020.107260_b0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40744-019-0149-3","article-title":"Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are Anti-CCP positive in the United States Corrona Registry","volume":"6","author":"Harrold","year":"2019","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2020.107260_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000345","article-title":"Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study","volume":"3","author":"Alten","year":"2017","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.intimp.2020.107260_b0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2020.107260_b0060","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.intimp.2020.107260_b0065","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"113","key":"10.1016\/j.intimp.2020.107260_b0070","article-title":"Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients","volume":"15","author":"Pappas","year":"2014","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"3","key":"10.1016\/j.intimp.2020.107260_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2020.107260_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2020.107260_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.intimp.2020.107260_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.107260_b0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/BOR.0b013e3283369cb8","article-title":"B cells in the pathogenesis and treatment of rheumatoid arthritis","volume":"22","author":"Marston","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.107260_b0100","doi-asserted-by":"crossref","first-page":"2364943","DOI":"10.1155\/2019\/2364943","article-title":"Characterization of T-Cell receptor repertoire in patients with rheumatoid arthritis receiving biologic therapies","volume":"2019","author":"Chang","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.intimp.2020.107260_b0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12967-014-0363-2","article-title":"Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients","volume":"13","author":"Imberti","year":"2015","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2020.107260_b0110","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3899\/jrheum.110386","article-title":"Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis","volume":"38","author":"Scarsi","year":"2011","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107260_b0115","first-page":"969","article-title":"Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis","volume":"35","author":"Zhao","year":"2008","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107260_b0120","first-page":"17","article-title":"Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease","volume":"51","author":"Mallya","year":"1983","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2020.107260_b0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.23.4.302","article-title":"A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor","volume":"23","author":"Nienhuis","year":"1964","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107260_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5114\/reum.2017.66680","article-title":"Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs","volume":"55","author":"Kumar","year":"2017","journal-title":"Reumatologia"},{"issue":"5","key":"10.1016\/j.intimp.2020.107260_b0135","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/art.40791","article-title":"Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis","volume":"71","author":"Darrah","year":"2019","journal-title":"Arthritis Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:23:14Z","timestamp":1761585794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920337279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":27,"alternative-id":["S1567576920337279"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107260","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107260"}}